BIOGEN SAYS CO CONTINUES TO ENFORCE ITS PATENTS, BUT BIOSIMILAR TO MS DRUG TYSABRI COULD LAUNCH UPON APPROVAL
Stock Market News in real time
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
202.5 USD | +0.23% | +6.27% | 29.36B | ||
- Stock Market
- Stock Market News in real time
- Economy
- Biogen Says Co Continues To Enforce Its Patents, But Biosimilar…